Moderna, Merck Revive mRNA Hopes With Melanoma Success

A personalized mRNA cancer [music] vaccine developed by Madna and Merc has achieved a major milestone in a latestage [music] clinical trial. Combined with Merc's amunotherapy drug Kitruda, the custom shot helped reduce the recurrence of melanoma and [music] slowed its spread to other parts of the body compared to Kitruda alone. Scientists [music] analyzed each patients tumor sample to create a tailored shot targeting [music] up to 34 unique mutations, training the immune system to hunt down remaining cancer ...